THERAPEUTICS
Refractory schizophrenia: adding aripiprazole to clozapine reduces negative but not overall symptoms
| The first 150 words of the full text of this article appear below. |
Does aripiprazole improve the antipsychotic effect of clozapine without increasing the risk of major adverse events in people with refractory schizophrenia?
61 Korean people, aged 18–65 years, with DSM-IV schizophrenia, a history of treatment failure, partial responsiveness to long term clozapine therapy (
1 year) and taking a stable clozapine dose for at least 3 months. Treatment failure was defined as persistent psychotic symptoms after at least two different antipsychotics at equivalent to
600 mg/day chlorpromazine for
6 weeks. Participants had to have a Brief Psychiatric Rating Scale (BPRS) score of
35 or >2 global rating items on the Schedule for Assessment of Negative Symptoms (SANS) score
3 (see online notes for exclusion criteria).
Refractory Schizophrenia Clinic, Seoul National University, Republic of Korea. Recruitment 1 December 2005 to 10 December 2006.
Aripiprazole (5–30 mg/day) or placebo for 8 weeks. An initial dose of 5 mg/day aripiprazole was administered and increased
University of Toronto and Centre for Addiction and Mental Health (CAMH), Toronto, Canada
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
